Edwards Lifesciences Corporation research snapshot
EW AI stock analysis currently reads Edwards Lifesciences as a focused structural heart company with leading TAVR scale, accelerating TMTT adoption, FY2026 sales growth guidance of 9% to 11%, and adjusted EPS guidance of $2.95 to $3.05. The caution is price discipline: at the July 8, 2026 data cutoff, EW closed at $94.82 on July 7, 2026, implying about $54.60 billion of verified market value, roughly 50x TTM EPS, and high expectations for continued procedure growth. This EW AI stock forecast uses scenarios, not a certain price prediction, and is for informational use only.
Current price
$94.82
Market cap
$54.60 billion verified market cap
AI score
74 / 100
Rating
High-quality structural heart leader with strong growth and valuation risk
Trend status
Constructive but extended, above the 50-day and 200-day moving averages with RSI near the upper end of neutral
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Edwards sells structural heart devices used in high-acuity procedures, led by SAPIEN TAVR, TMTT repair and replacement therapies, and surgical structural heart products. | High |
| Moat | The moat comes from clinical evidence, physician familiarity, product training, manufacturing know-how, regulatory approvals, hospital workflow integration, and a large installed base in TAVR. | High |
| Management | CEO Bernard Zovighian is focusing Edwards on structural heart after the Critical Care divestiture, with capital going to R&D, tuck-in innovation, and share repurchases. | Medium-high |
| Financial trend | FY2025 sales were $6.068 billion and continuing net income was $1.056 billion. Q1 2026 sales rose 16.7% to $1.649 billion, and adjusted EPS was $0.78. | High |
| Valuation | At $94.82, EW screens near 50.4x TTM EPS, 5.3x book value, 8.7x sales, 50.2x FCF, and 0% dividend yield based on audited tool math. | High |
| Technical trend | Price is above both 50-day and 200-day moving averages. StockAnalysis listed RSI near 69.92, so momentum is strong but close to an overbought warning zone. | Medium |
| Risk level | Key risks include TAVR competition, reimbursement changes, slower procedure growth, durability questions in younger patients, product liability, clinical trial setbacks, foreign exchange, and valuation compression. | Medium-high |
| AI confidence | High for current facts and calculations, medium for return ranges and chart timing. | High data confidence |
| Investment certainty | Medium. The business is better than average, but the current multiple requires continued execution in TAVR, TMTT, Surgical, margins, and capital allocation. | Medium |
EW AI stock forecast
The EW AI stock forecast is scenario-based because Edwards value depends on TAVR growth, TMTT adoption, reimbursement, clinical evidence, gross margin, R&D productivity, competition, and the market multiple assigned to medtech growth. Using the $94.82 price reference, FY2026 adjusted EPS guidance midpoint near $3.00, and the audited three-scenario model, the mechanical three-year framework points to about $86.80 in a bear case, $119.80 in a base case, and $151.10 in a bullish case before any buyback effect beyond the model assumptions.
$145 to $155 before buyback effect
More likely if adjusted EPS compounds near 14%, TAVR grows near the high end of guidance, TMTT scales faster than expected, CMS access expands, gross margin holds near guidance, and investors keep EW near a mid-30s earnings multiple.
$115 to $125 before buyback effect
More likely if sales grow around 9% to 11%, adjusted EPS compounds near 10%, TAVR remains stable, TMTT keeps gaining adoption, and EW trades around 30x forward earnings.
$82 to $90 before buyback effect
More likely if procedure growth slows, competitors take share, reimbursement or durability debate limits expansion, margin expansion stalls, or the market rerates high-multiple medtech stocks toward the mid-20s earnings range.
EW AI technical analysis
EW AI technical analysis is constructive but extended as of the July 8, 2026 data cutoff. StockAnalysis showed a July 7, 2026 close of $94.82, 50-day moving average near $85.80, 200-day moving average near $82.65, RSI near 69.92, and 20-day average volume near 4.63 million shares. Investing.com also showed EW above its 50-day and 200-day moving averages, with its 50-day reference near $90.08 and 200-day reference near $87.34. The setup favors trend discipline rather than chasing without an invalidation level.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $94.82 | StockAnalysis listed the July 7, 2026 close at $94.82, down 0.38% on the day. |
| Immediate support | $90 to $92 | This area overlaps recent breakout references and the Investing.com 50-day moving-average region. |
| 50-day moving average | $85.80 to $90.08 | StockAnalysis and Investing.com showed different 50-day references because of update timing and calculation source, but both were below the current price. |
| 200-day moving average | $82.65 to $87.34 | A sustained break below this zone would weaken the current constructive trend framework. |
| Near resistance | $95 to $96 | This is the first test after EW closed near recent highs in early July 2026. |
| Upper resistance | $100 to $105 | A move into this area likely needs Q2 results, raised guidance, or better evidence that TMTT can scale without pressuring margins. |
| Momentum | RSI near 69.92 | StockAnalysis placed RSI close to the classic 70 overbought threshold, so upside continuation needs confirmation. |
| Volume | 20-day average near 4.63 million shares | A breakout is more credible if volume is above the recent average and not just a low-volume drift. |
| Volatility | Moderate beta, high earnings sensitivity | StockAnalysis listed beta near 0.85, but high valuation can amplify moves around earnings, guidance, reimbursement, and clinical data. |
| Invalidation | Close below $82 to $87 | A sustained break below the 200-day moving-average zone would reduce confidence in the current EW AI technical analysis setup. |
EW AI trading strategy
The EW AI trading strategy below is a rules-based research framework, not personal advice. It connects price levels with TAVR growth, TMTT adoption, surgical structural heart demand, EPS guidance, margin targets, CMS reimbursement review, clinical trial data, competition, and valuation discipline.
Watch for EW to hold above the $90 to $92 area and then clear $95 to $96 on volume above recent averages, ideally with unchanged or higher FY2026 guidance and no negative update on TAVR competitive position.
A failed breakout followed by a close below the 50-day moving-average zone should reduce trend confidence because RSI is already near the upper end of neutral.
If EW pulls back toward the mid-to-high $80s while guidance remains intact, compare the lower price with expected adjusted EPS growth, TMTT adoption, gross margin, R&D pipeline progress, and buyback capacity.
Do not treat a pullback as automatically cheap. Recheck whether TAVR share, reimbursement, clinical evidence, or margin assumptions changed.
Track Q2 2026 sales, adjusted EPS, TAVR growth versus the 7% to 9% guide, total sales versus the $6.5 billion to $6.9 billion guide, TMTT progress, surgical structural heart growth, gross margin, R&D spending, CMS NCD updates, and share repurchase pace.
Position sizing should reflect that EW is a high-quality but high-multiple medtech stock. Multiple compression can offset good operating execution.
Investment research summary
Edwards is paid when hospitals and physicians use its structural heart devices to treat serious valve disease. Customers pay because TAVR, TMTT, and surgical valve products can address urgent clinical needs with proven device platforms and specialist support.
The moat is built on clinical data, physician trust, procedure training, regulatory approvals, manufacturing quality, product iteration, and a large TAVR installed base. It is not pure brand power because outcomes, reimbursement, and clinical evidence keep resetting the competitive test.
The thesis fails if TAVR growth slows, younger-patient durability concerns limit expansion, CMS or international reimbursement becomes less favorable, competitors gain share, TMTT adoption disappoints, or product liability and litigation costs rise.
Management should be judged by whether the post-Critical Care Edwards remains focused, funds R&D productively, defends TAVR leadership, scales TMTT, keeps margin discipline, and uses buybacks at prices that do not destroy per-share value.
Structural heart treatment is tied to aging populations, less invasive procedures, earlier diagnosis, clinical evidence, and hospital adoption. The trend is favorable, but procedure growth depends on referral patterns, reimbursement, capacity, and physician confidence.
At roughly 50x TTM EPS and about 8.7x sales, EW has less margin of safety than the business quality alone suggests. Margin improves if the stock retreats while guidance and clinical momentum remain intact.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Share price | $94.82 close on July 7, 2026 | StockAnalysis EW financials | July 8, 2026 |
| Market capitalization | $54.60 billion, verified as $94.82 x 575.8 million shares | StockAnalysis EW statistics and financial_rigor.py | July 8, 2026 |
| Shares outstanding | 575.8 million shares | StockAnalysis EW statistics | July 8, 2026 |
| FY2025 sales | $6.068 billion | Edwards Lifesciences FY2025 results | July 8, 2026 |
| FY2025 continuing net income | $1.056 billion | Edwards Lifesciences 2025 Form 10-K | July 8, 2026 |
| Q1 2026 sales and adjusted EPS | $1.649 billion sales, $0.78 adjusted EPS | Edwards Lifesciences Q1 2026 results | July 8, 2026 |
| FY2026 guidance | $6.5 billion to $6.9 billion sales, $2.95 to $3.05 adjusted EPS | Edwards Lifesciences Q1 2026 results | July 8, 2026 |
| Cash and short-term investments | $3.672 billion as of March 31, 2026 | StockAnalysis EW balance sheet | July 8, 2026 |
| Total debt | $702.9 million as of March 31, 2026 | StockAnalysis EW balance sheet | July 8, 2026 |
| Technical trend | 50-day MA near $85.80, 200-day MA near $82.65, RSI near 69.92 | StockAnalysis EW statistics | July 8, 2026 |
| Alternative moving-average reference | 50-day MA near $90.08, 200-day MA near $87.34 | Investing.com EW technical summary | July 8, 2026 |
| Risk factor categories | Innovation, clinical trials, manufacturing, competition, reimbursement, regulation, IP, product liability, cybersecurity, and international risks | Edwards Lifesciences 2025 Form 10-K | July 8, 2026 |
This EW AI stock analysis page is an informational research tool, not investment advice, a recommendation, or a personalized trading plan. Forecast scenarios are based on available public data as of July 8, 2026 and can be wrong if earnings, clinical evidence, reimbursement, competition, valuation multiples, or market conditions change.
